Yoshie Umemura, MD, discusses the development of ONC201 in patients with H3K27M-mutated diffuse midline glioma.
Tracking the Development of Novel Drugs in Glioma
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.
Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.
Ashley Sumrall, MD, FACP, discusses ongoing research with the DRD2 dopamine receptor–targeted agent ONC201 in patients with H3K27M-mutated glioma.
Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5